Lode Debrabandere, PhD, MBA, serves as co-founder & CEO of Amynas, BV. Prior to Amynas, he founded two other regenerative medicine companies. He also served as President & CEO of Osiris Therapeutics (acquired by Smith & Nephew). Prior to Osiris, Dr. Debrabandere was Vice President of Marketing at Bristol-Myers Squibb. He led the Neuroscience Business Unit and was the Global Brand Leader for Abilify, the second largest brand of the company, behind Plavix. Prior to Bristol-Meyers Squibb, Dr. Debrabandere had leadership roles at the US subsidiary of UCB Pharma. In 1995, he was expatriated by UCB Pharma from Brussels, Belgium to Atlanta, GA to establish UCB’s presence in the US. Dr. Debrabandere earned an MBA, a PhD in pharmaceutical sciences, toxicology, and a PharmD degree, from the Catholic University of Leuven, Belgium.
Lode Debrabandere, PhD, MBA, serves as co-founder & CEO of Amynas, BV. Prior to Amynas, he founded two other regenerative medicine companies. He also served as President & CEO of Osiris Therapeutics (acquired by Smith & Nephew). Prior to Osiris, Dr. Debrabandere was Vice President of Marketing at Bristol-Myers Squibb. He led the Neuroscience Business Unit and was the Global Brand Leader for Abilify, the second largest brand of the company, behind Plavix. Prior to Bristol-Meyers Squibb, Dr. Debrabandere had leadership roles at the US subsidiary of UCB Pharma. In 1995, he was expatriated by UCB Pharma from Brussels, Belgium to Atlanta, GA to establish UCB’s presence in the US. Dr. Debrabandere earned an MBA, a PhD in pharmaceutical sciences, toxicology, and a PharmD degree, from the Catholic University of Leuven, Belgium.
17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy